Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey

• Published in: European Radiology
• Main Authors: Sardanelli, Francesco, Aase, Hildegunn, Álvarez, Marina, Azavedo, Edward, Baarslag, Henk, Balleyguier, Corinne, Baltzer, Pascal, Beslagic, Vanesa, Bick, Ulrich, Bogdanovic-Stojanovic, Dragana, Briediene, Ruta, Brkljacic, Boris, Camps Herrero, Julia, Colin, Catherine, Cornford, Eleanor, Danes, Jan, de Geer, Gérard, Esen, Gul, Evans, Andrew, Fuchsjaeger, Michael, Gilbert, Fiona, Graf, Oswald, Hargaden, Gormlaith, Helbich, Thomas, Heywang-Köbrunner, Sylvia, Ivanov, Valentin, Jónsson, Ásbjörn, Kuhl, Christiane, Lisencu, Eugenia, Luczynska, Elzbieta, Mann, Ritse, Marques, José, Martincich, Laura, Mortier, Margarete, Müller-Schimpfle, Markus, Ormandi, Katalin, Panizza, Pietro, Pediconi, Federica, Pijnappel, Ruud, Pinker, Katja, Rissanen, Tarja, Rotaru, Natalia, Saguatti, Gianni, Sella, Tamar, Slobodníková, Jana, Talk, Maret, Taourel, Patrice, Trimboli, Rubina, Vejborg, Ilse, Vourtsis, Athina, Forrai, Gabor
• Other Authors: Università degli Studi di Milano = University of Milan (UNIMI), Haukeland University Hospital, University of Bergen (UiB), Hospital Reina Sofia, Cordoba, Karolinska University Hospital Stockholm, Meander Medical Center, Département d'imagerie médicale Gustave Roussy, Institut Gustave Roussy (IGR), Medizinische Universität Wien = Medical University of Vienna, Clinical Center University of Sarajevo, Charité - UniversitätsMedizin = Charité - University Hospital Berlin, Institutski put 4, Vilnius University Vilnius, University Hospital Centre Zagreb and University of Zagreb School of Medicine, Hospital de la Ribera, Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL), Nottingham University Hospitals NHS Trust (NUH), Computer Science Institute of Charles University Prague (IUUK), Charles University Prague (CU), ImageRive, Acibadem University, Ninewells Hospital and Medical School Dundee, Medical University Graz, University of Cambridge UK (CAM), Mater Misericordiae University Hospital (The Mater Hospital), Tokuda Hospital Sofia, Value Chain, Processing and Aquaculture, Matis Ohf Food Safety Environm & Genet, Landspitalinn University Hospital, Reykjavik, Department of Medicine III, University hospital (UKA), University of Aachen (RWTH), Rheinisch-Westfälische Technische Hochschule Aachen University (RWTH)-University hospital (UKA), The Oncology Institute 'Prof. Dr. Ion Chiricuta', Radboud University Medical Center Nijmegen, University of Coimbra Portugal (UC), Ghent University Hospital, Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)
• Format: Article in Journal/Newspaper
• Language: English
• Published: HAL CCSD 2017
• Subjects: Breast cancer; Digital breast tomosynthesis (DBT); Digital mammography; Population-based screening; Recall rate; [SDV]Life Sciences [q-bio]; Norway; Iceland
• Online Access: https://hal.umontpellier.fr/hal-01806845; https://doi.org/10.1007/s00330-016-4612-z

International audience EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for women aged 50-69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1-10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40-49 years and 70-74 years, although with "limited evidence". Thus, we firstly recommend biennial screening mammography for average-risk women aged 50-69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40-45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become "routine mammography" in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged.